A Phase 2 Randomized, Double-blind, Placebo-controlled, Multicenter Study of the Efficacy and Safety of AL002 in Patients with Prodromal to Mild Alzheimer’s Disease
What is this Study about?
Participants will receive drug treatment via IV in clinic on Day 1 and every 4 weeks thereafter.
What Will Happen in This Study?
The total duration of study participation for each participant will be up to approximately 115 weeks, including treatment period of a minimum of 48 weeks, and a maximum of 96 weeks.
Who is Eligible to Participate in this Study?
- Age 50-85 years old
- Diagnosis of early AD
Any materials or links provided herein are strictly for informational purposes only. The Alzheimer Society of Canada does not endorse nor recommend any of the manufacturers, products or institutions mentioned in any of these links or listings as suitable or appropriate for your particular situation or circumstances and disclaims any liability with respect to representations, warranties, including fitness for an intended particular use or purpose, and all other claims relating thereto, all of which remain strictly with the manufacturer or institution.
In no event shall the Alzheimer Society of Canada or any third parties mentioned on the website be liable for any damage (including, without limitation, incidental and consequential damages for personal injury/wrongful death, lost profits or damages resulting from lost data or business interruption) or personal injury (including death) resulting from the use, misuse or inability to use any activity, product or service mentioned herein, whether based in warranty, contract, tort or any other legal theory.
Everyone considering participating in any activity is encouraged to speak with their own doctor or health-care team before participating in any activity that may impact their health or well-being.